30 closest matches · ranked by relevance
Breast Cancer · Triple Negative Breast Cancer · Stage IV Breast Cancer
Primary: Objective Response Rate — 28; 38 percentage of patients
Breast Cancer
Primary: Clinical Benefit Rate — 0.12 proportion of participants
Triple-Negative Breast Cancer
Primary: Percentage of Participants With Treatment-emergent Grade ≥3 Adverse Events (AEs) — 46.70 percentage of participants
Triple Negative Breast Cancer
Primary: Number of Participants With Pathologic Response by HR-deficiency (HRD) Status — 9; 2; 10; 4 Participants
Triple Negative Breast Cancer
Primary: 3 Months Progression Free Survival. Probability That the Cancer Has Not Progressed at 3 Months Calculated With Kaplan Meier. — 15.8 perceent probability at 3 months
Breast Cancer
Primary: Objective Response Rate — 0.09 proportion of participants
Metastatic Breast Cancer
Primary: Progression-free Survival (PFS) — 4.4 Months
Triple Negative Breast Cancer
Primary: Efficacy (Objective Response Rate) — 1 Participants
Metastatic Triple Negative Breast Cancer
Primary: Overall Response Rate (ORR) in Patients Treated With CNP — 2; 11; 6; 8 Participants
Triple Negative Breast Cancer · Breast Neoplasms
Primary: Safety and Tolerability Adverse Events — 8; 81 Total events
Breast Cancer
Primary: Objective Response Rate — 3; 19; 4; 57 Participants
Stage I Breast Cancer AJCC v7 · Stage IA Breast Cancer AJCC v7 · Stage IB Breast Cancer AJCC v7
Primary: Number of Participants With Residual Disease — 24 Participants
Breast Cancer · Metastasis
Primary: Number of Participants With Complete Response (CR) or Partial Response (PR) — 2; 0 participants
Breast Cancer
Primary: Two-year Disease Free Survival — 54.2; 64.1 percentage of participants
Triple-negative Breast Cancer
Primary: Number of Participants With Pathological Complete Response — 26; 28 Participants
Breast Cancer
Primary: Phase II: The Number of Subjects Exhibiting Pathologic Complete Response to Neoadjuvant Treatment With Sunitinib/Paclitaxel/Carboplatin — 12 participants
Breast Cancer
Primary: Best Clinical Response Expressed as Percentage of Participants Treated With Combination Regimen of Weekly Abraxane® and Carboplatin Plus Biweekly Bevacizumab to Treat…
Breast Tumor · Breast Cancer · Cancer of the Breast
Primary: Kaplan-Meier Estimates of Progression-Free Survival (PFS) Based on Investigator Assessment. — 5.5; 8.3; 6.0 months — p=0.0183
Triple Negative Breast Cancer
Primary: Efficacy (Objective Response Rate) — 3 Participants
Advanced Breast Cancer · HER2/Neu Negative · Triple-Negative Breast Cancer
Primary: Objective Response (OR) — 0; 0; 0; 3 Participants
Breast Cancer · Triple Negative Breast Cancer
Primary: Tumor Response — 22 Participants
Metastatic Triple Negative Breast Cancer
Primary: Asses the Maximum Tolerated Dose (MTD) of L-NMMA When Combined With Docetaxel/Amlodipine in the Treatment of Refractory Locally Advanced or Metastatic TNBC Patients…
Breast Cancer
Primary: Complete Response Rate — 2; 8 Participants
Breast Neoplasm
Primary: Best Overall Response (BOR) — 20.0; 10.3 percentage of participants — p=0.1109
Malignant Neoplasm of Breast · Breast Cancer
Primary: Percentage of Participants With Two-Year Disease-Free Survival (DFS) — 56.6; 62.4 percentage of participants
Breast Neoplasms
Primary: Progression-Free Survival (PFS) — 2.0; 2.7; 1.7; 2.5 Months — p=0.8885
Estrogen Receptor Negative · HER2/Neu Negative · Invasive Breast Carcinoma
Primary: Objective Response Rate (ORR), Defined as the Proportion of Patients Who Have Had a Partial Response (PR) or Complete Response (CR) (RECIST 1.1 Based) Within the First 6…
Breast Cancer
Primary: Change From Baseline in Functional Assessment of Cancer Therapy-Breast Cancer (FACT-B) Score at Cycle 2 — 98.3; 102.21; 5.83; -2.48 units on a scale
Breast Cancer
Primary: Rate of Clinical Benefit — 0; 0; 6; 11 Participants
Triple-Negative Breast Cancer
Primary: Progression-Free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Subpopulation With Programmed Death-Ligand 1…